A5021020671- Coronary Interventions and Diagnostics
- Coronary Artery Anomalies
- Cardiac Health and Mental Health
- Lipoproteins and Cardiovascular Health
- Cardiac Imaging and Diagnostics
- Heart Failure Treatment and Management
- Venous Thromboembolism Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiac Arrhythmias and Treatments
- Peripheral Artery Disease Management
- Cardiac Valve Diseases and Treatments
- Medication Adherence and Compliance
- Hemodynamic Monitoring and Therapy
- Protease and Inhibitor Mechanisms
- Geriatric Care and Nursing Homes
- Vascular anomalies and interventions
- Cardiovascular Disease and Adiposity
- Heparin-Induced Thrombocytopenia and Thrombosis
- Stroke Rehabilitation and Recovery
- Workplace Health and Well-being
- Natural Products and Biological Research
- Homelessness and Social Issues
- Aortic Thrombus and Embolism
Centre universitaire de médecine générale et santé publique, Lausanne
2025
University of Lausanne
2025
Thomas Jefferson University
2011-2023
Thomas Jefferson University Hospital
2013-2023
Clinical Research Institute
2016-2022
MedStar Georgetown University Hospital
2021
Georgetown University
2021
Philadelphia University
2013-2015
Center for Clinical Research (United States)
2012
Jefferson College
2012
As patients with heart failure experience worsening of their condition, including acute decompensated failure, quality life deteriorates. However, the trajectory changes and determinants in context Rehabilitation Therapy Older Acute Heart Failure Patients trial physical rehabilitation intervention are unknown.
Introduction: Adherence to medications for secondary prevention of cardiovascular events has been shown be poor in both general and high risk populations. Non-adherent patients are at higher experiencing another CV event, leading adverse clinical costs. Few prior studies have explored the economic consequences non-adherence aspirin relation health. Hypothesis: Improved adherence will lead lower healthcare costs improved long-term survival rates. Methods: We developed a generalizable Markov...
Introduction: Drug-eluting stents (DES) have been shown to superior short term outcomes in the treatment of saphenous vein graft (SVG) disease compared bare metal stents. Hypothesis: The goal this study was assess long clinical outcome all patients with SVG treated DES. Methods: 183 consecutive undergoing intervention DES were evaluated. Post-procedure, antiplatelet therapy included aspirin indefinitely and dual for a minimum 1 year. Major adverse cardiac events (MACE) assessed at mean...
Although drug-eluting stents (DESs) have significantly reduced restenosis after percutaneous coronary intervention (PCI), repeat target vessel revascularization (TVR) treatment with new-generation DES is approximately 10% at 2 years.1Silber S. Windecker Vranckx P. Serruys RESOLUTE All Comers Investigators. Unrestricted randomized use of two new generation stents: 2-year patient-related versus stent-related outcomes from the trial.Lancet. 2011; 377: 1241-1247Abstract Full Text PDF PubMed...
Background: Percutaneous coronary intervention (PCI) of diseased saphenous vein grafts (SVG) is associated with a high risk ischemic events. Even when distal protection devices are used, periprocedural complications still occur in 5 to 10% patients. The aim this study was identify predictive factors for during SVG interventions performed protection. Methods: Clinical outcomes were assessed 163 consecutive patients undergoing PCI devices. primary outcome the occurrence major adverse cardiac...